Microcap Ledger TELA Bio, Inc. $TELA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- Malvern, PA
- Fiscal year end
- December 31
- Shares outstanding
- 44,894,757 [10-Q 2026-08-11]
What the company doesAI summary of filing
TELA Bio is a commercial-stage medical technology company that develops and sells reinforced tissue matrices for soft-tissue reconstruction. The company's primary products are OviTex and OviTex PRS, which combine biologic material from ovine rumen with interwoven polymer fibers and are used in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. TELA Bio generates revenue through direct sales in the U.S. and Europe, with 2025 revenues of $80.3 million, though the company reported a net loss of $38.8 million and maintains an accumulated deficit of $397.6 million. [10-K 2026-03-25]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $38.35M | −$23.54M | −$20.55M | $30.42M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | $80.28M | −$38.80M | −$28.22M | $50.84M | [10-K 2026-03-25] |
| FY ended Dec 2024 | $69.30M | −$37.80M | −$41.59M | $52.67M | [10-K 2026-03-25] |
- Quarterly cash burn
- −$10.28M
- Cash runway Estimate
- ~8.9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 39,388,443 | [10-Q 2024-11-08] |
| 2025-03-14 | 39,551,098 | [10-K 2025-03-21] |
| 2025-05-01 | 39,554,989 | [10-Q 2025-05-08] |
| 2025-08-04 | 39,616,440 | [10-Q 2025-08-11] |
| 2025-11-03 | 40,341,535 | [10-Q 2025-11-14] |
| 2026-03-16 | 44,740,371 | [10-K 2026-03-25] |
| 2026-05-05 | 44,766,146 | [10-Q 2026-05-13] |
| 2026-08-05 | 44,894,757 | [10-Q 2026-08-11] |
- Shelf registration
- S-3 filed 2025-12-12; declared effective 2025-12-18 [S-3 2025-12-12]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-09-18. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-09-18 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-09-18] |
| 2026-03-20 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-03-20] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-17 | Capper Joseph H | buy | 25,000 | $1.22 | [4 2026-09-18] |
| 2026-09-16 | Capper Joseph H | buy | 50,000 | $1.17 | [4 2026-09-18] |
| 2026-09-15 | Capper Joseph H | buy | 50,000 | $1.06 | [4 2026-09-16] |
| 2026-09-14 | Capper Joseph H | buy | 25,000 | $1.02 | [4 2026-09-16] |
| 2026-08-17 | Getz Heather C | buy | 12,500 | $0.66 | [4 2026-08-19] |
| 2026-08-14 | Getz Heather C | buy | 15,000 | $0.70 | [4 2026-08-17] |
| 2026-08-03 | Getz Heather C | grant | 500,000 | — | [4 2026-08-05] |
| 2026-07-15 | Plovanic William J. | grant | 20,930 | $0.79 | [4 2026-07-17] |
| 2026-07-15 | Capper Joseph H | grant | 6,227 | $0.79 | [4 2026-07-17] |
| 2026-06-09 | Rocchio Betty Jo | grant | 11,675 | — | [4 2026-06-11] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-08 | 8-K | Shareholder vote results |
| 2026-10-06 | 8-K | Other events |
| 2026-10-05 | 8-K | Other events |
| 2026-09-29 | 8-K | Material agreement entered |
| 2026-09-18 | 8-K | Listing notice or transfer |
| 2026-09-14 | DEF 14A | Proxy statement |
| 2026-09-04 | PRE 14A | Proxy statement |
| 2026-08-31 | 8-K | Exit or disposal costs; Director or officer change; Regulation FD disclosure |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 8-K | Director or officer change |
| 2026-08-11 | 10-Q | Quarterly report |
Alerts for $TELA
Email me when TELA Bio, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.